Produto adicionado correctamente ao carrinho.

discount label
H-KLVALGINAV-OH
Ver 3D

Biosynth logo

H-KLVALGINAV-OH

Ref. 3D-PP45226

1mg
232,00 €
10mg
273,00 €
100mg
497,00 €
Entrega estimada em Estados Unidos, Sexta-feira 27 de Dezembro de 2024

Informação sobre produto

Nome:
H-KLVALGINAV-OH
Sinónimos:
  • NH2-Lys-Leu-Val-Ala-Leu-Gly-Ile-Asn-Ala-Val-OH
Descrição:

Peptide H-KLVALGINAV-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-KLVALGINAV-OH include the following: How an alloreactive T-cell receptor achieves peptide and MHC specificity Y Wang , NK Singh , TT Spear - Proceedings of the , 2017 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1700459114 Clonal deletion prunes but does not eliminate self-specific alphabeta CD8+ T lymphocytes W Yu, N Jiang , PJR Ebert, BA Kidd , S Muller, PJ Lund - Immunity, 2015 - cell.comhttps://www.cell.com/immunity/pdf/S1074-7613(15)00181-8.pdf Inefficient recognition of autologous viral sequences by intrahepatic hepatitis C virus-specific cytotoxic T lymphocytes in chronically infected subjects VM Giuggio, HL Bonkovsky, J Smith, AL Rothman - Virology, 1998 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0042682298994016 Characterization of intrahepatic T-lymphocytes in patients with chronic hepatitis C virus infection: a dissertation VM Giuggio - 2000 - repository.escholarship.umassmed https://repository.escholarship.umassmed.edu/handle/20.500.14038/31507 Liver Organoid and T Cell Coculture Models Cytotoxic T Cell Responses against Hepatitis C Virus V Natarajan , CR Simoneau, AL Erickson, NL Meyers - Biorxiv, 2021 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2021.08.10.455738.abstract Modelling T-cell immunity against hepatitis C virus with liver organoids in a microfluidic coculture system V Natarajan , CR Simoneau , AL Erickson - Open , 2022 - royalsocietypublishing.orghttps://royalsocietypublishing.org/doi/abs/10.1098/rsob.210320 Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability TT Spear, TP Riley, GE Lyons - Journal of Leucocyte , 2016 - academic.oup.comhttps://academic.oup.com/jleukbio/article-abstract/100/3/545/6932858 Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity RH McMahan , L Golden-Mason - The Journal of , 2010 - Am Soc Clin Investighttps://www.jci.org/articles/view/43127 Determinants of viral clearance and persistence during acute hepatitis C virus infection R Thimme, D Oldach, KM Chang , C Steiger - The Journal of , 2001 - rupress.orghttps://rupress.org/jem/article-abstract/194/10/1395/39380 Hepatitis C virus immune escape via exploitation of a hole in the T cell repertoire M Wölfl, A Rutebemberwa, T Mosbruger - The Journal of , 2008 - journals.aai.orghttps://journals.aai.org/jimmunol/article/181/9/6435/78899 IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses JW Han , PS Sung , SH Hong , H Lee , JY Koh , H Lee - Journal of , 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0168827820301070 Cutting edge: identification of hepatitis C virus-specific CD8+ T cells restricted by donor HLA alleles following liver transplantation HR Rosen, DJ Hinrichs, RL Leistikow - The Journal of , 2004 - journals.aai.orghttps://journals.aai.org/jimmunol/article/173/9/5355/36231 Transplantation immunology: what the clinician needs to know for immunotherapy HR Rosen - Gastroenterology, 2008 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0016508508003004 Targeting naturally occurring epitope variants of hepatitis C virus with high-affinity T-cell receptors H Zhang, J Zhang, L Chen, Z Weng - Journal of General , 2017 - microbiologyresearch.orghttps://www.microbiologyresearch.org/content/journal/jgv/10.1099/jgv.0.000656 Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C FX Lopez-Labrador, XS He - Journal of medical , 2004 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20036 Hepatitis C virus-specific cellular and humoral immune responses following immunization with a multi-epitope fusion protein F Qiu, S Bi, Y Wang, M Guo, Y Yi - International , 2012 - spandidos-publications.comhttps://www.spandidos-publications.com/ijmm/29/1/12 Identification of naturally processed hepatitis C virus-derived major histocompatibility complex class I ligands B Wölk, C Trautwein, B Buchele, N Kersting, HE Blum - PloS one, 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0029286&imageURI=info:doi/10.1371/journal.pone.0029286.g003 The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1 AY Kim, GM Lauer , K Ouchi , MM Addo , M Lucas - Blood, 2005 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/105/3/1170/19641 Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall AK Thomas-Kaskel, R Zeiser , R Jochim - Journal of Cancer, 2006 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.22097 RACER-m leverages structural features for sparse T Cell specificity prediction A Wang , X Lin , KN Chau , JN Onuchic , H Levine - Science , 2024 - science.orghttps://www.science.org/doi/abs/10.1126/sciadv.adl0161 Strong CD8+ T cell antigenicity and immunogenicity of large foreign proteins incorporated in HIV-1 VLPs able to induce a Nef-dependent activation/maturation of A Sistigu, L Bracci , M Valentini, E Proietti, R Bona - Vaccine, 2011 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X11002945

Aviso:
Os nossos productos estão destinados exclusivamente para uso em laboratório. Para qualquer outra aplicação, por favor entre em contacto.
Marca:
Biosynth
Armazenamento a longo prazo:
Notas:

Propriedades químicas

MDL:
Ponto de fusão:
Ponto de ebulição:
Ponto de inflamação:
Densidade:
Concentração:
EINECS:
Merck:
Código HS:

Informação sobre riscos

Número ONU:
EQ:
Classe:
Frases H:
Frases P:
Proibido de voar:
Informação sobre riscos:
Grupo de Embalagem:
LQ:

Consulta técnica sobre: 3D-PP45226 H-KLVALGINAV-OH

Por favor, utilize o carrinho para solicitar um orçamento ou uma encomenda

Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.

* Campos obrigatórios
Bem-vindo à CymitQuimica!Usamos cookies para melhorar sua visita. Não incluímos publicidade.

Consulte a nossa Política de Cookies para mais detalhes ou ajuste suas preferências em "Configurar".